Safety of PDT-Photofrin® Prior to Lung Surgery

A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection

This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA. Participation will last 4 months.

Study Overview

• Status: Completed
• Conditions: Lung Cancer; Lung Cancer Metastatic
• Intervention / Treatment: Drug: Porfimer Sodium; Device: Fiber optic

Detailed Description

Lung cancer accounts for almost one-third of cancer deaths. Cancer screening strategies have the potential to achieve a 20% reduction in death rates. Newly developed bronchoscopic technologies (such as navigational bronchoscopy) have been shown to enable physicians to safely reach lesions in peripheral regions of the lung and obtain diagnosis. This new technology may now potentially offer bronchoscopic therapeutic interventions, such as photodynamic therapy, to tumors that were previously unreachable due to their peripheral anatomic location.

Photodynamic therapy (PDT) uses a combination of a photosensitizing drug (a drug that is activated by light), called porfimer sodium (Photofrin®), and a light from a laser that emits no heat. This technique works to allow the medical doctor to specifically target and destroy abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation of the drug is done by lightning the abnormal area using a fiber optic device (very fine fiber [like a fishing line] that permits light transmission) inserted into a flexible tube with a light, called bronchoscope for the lung. The light activates the porfimer sodium concentrated in the abnormal tissue, leading to its destruction.

The purpose of this study is to assess the safety of using photodynamic therapy prior to surgical resection of tumors located in the periphery of the lung.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90048
      • Cedars-Sinai Medical Center
  • Colorado
    • Denver, Colorado, United States, 80045
      • University of Colorado
  • Florida
    • Tampa, Florida, United States, 33612
      • Moffitt Cancer Center
  • Georgia
    • Atlanta, Georgia, United States, 30265
      • Cancer Treatment Centers of America/Southeastern
  • Illinois
    • Elk Grove Village, Illinois, United States, 60007
      • AMITA Health Alexian Brothers Medical Center
  • Pennsylvania
    • DuBois, Pennsylvania, United States, 15801
      • Dubois Medical Center
  • Texas
    • Houston, Texas, United States, 77030
      • UT MD Anderson Cancer Center
  • Washington
    • Spokane, Washington, United States, 99204
      • Providence Health & Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female aged 18-79
• Diagnosed with primary or metastatic tumor < 5 cm located in peripheral lung that can be completely resectable
• Candidate for surgical resection
• Candidate for bronchoscopy
• Tumor is accessible for unrestricted illumination of PDT
• Subject is deemed likely to survive for at least 3 months
• Non-menopausal/non-sterile female subject of childbearing potential has negative B-HCG (Human chorionic gonadotropin) at time of study entry
• Non-menopausal/non-sterile female subject of childbearing potential uses medically acceptable form of birth control
• Subject is able and willing to provide written informed consent to participate in the study, which must comply with ICH (International Council for Harmonisation) guidelines & local requirements

Exclusion Criteria:

• Diagnosis of small cell lung cancer or carcinoid tumors
• Primary or metastatic lung tumor located in central lung or near vertebral body
• Tumor invades a major blood vessel
• Presence of concurrent non-solid malignancy
• Tumor previously treated with radiation therapy
• Chemotherapy in the last four weeks
• Tumor treated with PDT within the last 3 months
• Abnormal blood results
• Subject with porphyria or hypersensitivity to Photofrin
• Coexisting ophthalmic disease likely to required slit-lamp exam within next 90 days
• Acute or chronic medical or psychological illness as judged clinical significant to PI to preclude bronchoscopy procedures
• female who is breast-feeding or intends to breast-feed during study
• subject who participated in another study within last 30 days or intends to participate in another study during this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Photodynamic therapy-Photofrin; Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.

Drug: Porfimer Sodium; Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.; Other Names: Photofrin; Device: Fiber optic; After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Number of Participants With at Least One Adverse Event	Safety evaluation will include incidence of all adverse events, including serious and non-serious. The count of how many subjects experienced at least one adverse event.	108 days (to 3 months post surgery)
Safety: Physical Examination Summaries of Non-normal Findings for Each Subject	Safety evaluation will include the physical examinations summary of non-normal findings for each subject.	108 days (to 3 months post surgery)
Safety: Vital Sign Summary of Abnormal Findings for Each Subject	Safety evaluation will include vital sign summary for each subject. Only abnormal counts are included.	108 days (to 3 months post surgery)
Safety: Laboratory Tests Summaries of Abnormal Findings for Each Subject	Safety evaluation will include laboratory tests summarized for each subject with any abnormal lab results considered an AE (adverse event) to be listed.	108 days (to 3 months post surgery)
Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject	Safety evaluation will include incidence of skin photosensitivity summarized for each subject.	108 days (to 3 months post surgery)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Macroscopic Tissue Examination	The mean measurement of tumor size after surgery. The largest diameter seen is measured.	Day 13 to 18
Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery	The Percentage of Participants with Complete Response in Tumor area (no non-viable/necrotic tumor) after surgery	Day 13 to 18
Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery	The mean with standard deviation of the percent of tumor cell necrosis in the tumor area after surgery. The tumor itself was examined after it was removed to determine the percent of necrosis seen.	Day 13 to 18
Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery	The number of participants showing a brisk inflammatory reaction in the tumor area after surgery. This is determined through a histological examination. Brisk Inflammatory Reaction is defined as lymphocytes that infiltrate diffusely the entire tumor and/or infiltrate across the entire base of the tumor.	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery	The number of participants with cavitation seen in the normal lung area from the microscopic tissue examination after surgery	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery	The Number of Participants with hemorrhage seen during the microscopic tissue examination after surgery	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery	The Number of Participants with pneumonitis seen in the normal lung area after surgery following the microscopic tissue examination	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery	The number of participants with increased alveolar macrophages post surgery determined in the microscopic tissue examination.	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery	Number of Participants with Atypical/Reactive Type 2 pneumocytes seen in the normal lung after surgery during the Microscopic Tissue Examination:	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery	Number of Participants with Mucus Plugging/Mucositis seen in the normal lung after surgery during the Microscopic Tissue Examination.	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Interstitial Fibrosis in the Normal Lung After Surgery	Number of participants with interstitial fibrosis in the normal lung after surgery seen during the Microscopic Tissue Examination	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery	Number of Participants with Necrosis seen in the normal lung after surgery during the Microscopic Tissue Examination	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery	Number of Participants with Large Vessel Damage indicated by fibrinoid necrosis, thrombus, vasculitis in the normal lung after surgery seen during Microscopic Tissue Examination	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery	Number of Participants with Acute Alveolar damage in the normal lung after surgery seen during the Microscopic Tissue Examination	Day 13 to 18
Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery	Number of Participants with Organizing pneumonia pattern in the normal lung after surgery seen during Microscopic Tissue Examination	Day 13 to 18
ECOG (Eastern Cooperative Oncology Group) Performance Status: Baseline	Number of Participants with ECOG Performance at Baseline showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	Baseline (-30 to -1 Days)
ECOG Performance Status: Period 1 PDT Day 3	Number of Participants with ECOG Performance Status at Period 1 PDT Day 3, showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	Day 3
ECOG Performance Status: Period II Surgery (Day 13-18)	Number of Participants with ECOG Performance Status at Period II Surgery (Day 13-18) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	Day 13 to 18
ECOG Performance Status: Period III Follow-up (Day 20-25)	Number of Participants with ECOG Performance Status at Period III Follow-up (Day 20-25) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	Day 20 to 25
ECOG Performance Status: Period III Follow-up (Day 43 -48)	Number of Participants with ECOG Performance Status at Period III Follow-up (Day 43 -48) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	Day 43 to 48
ECOG Performance Status: Period III Follow-up (Day 103 - 108)	Number of Participants with ECOG Performance Status at Period III Follow-up (Day 103 - 108) showing the number of participants at each ECOG level. ECOG is Eastern Cooperative Oncology Group. ECOG has 6 levels (0-5). Level 0 is the best status (fully active, able to carry on all pre-disease performance without restriction); Level 1 is mildly restricted (Restricted in physically strenuous activity but ambulatory ad able to carry out work of a light or sedentary nature, e.g. light house work, office work); Level 2 is more restricted (Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours); Level 3 is restricted (Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours); Level 4 is highly restricted (completely disabled; cannot carry on any selfcare; totally confined to bed or chair); and Level 5 is death (dead).	108 days (to 3 months post surgery)

Collaborators and Investigators

• Sponsor: Concordia Laboratories Inc.
• Investigators: Study Chair: Erin O'Neil, Concordia Laboratories Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 14, 2017
• Primary Completion (Actual): March 22, 2019
• Study Completion (Actual): March 22, 2019

Study Registration Dates

• First Submitted: November 13, 2017
• First Submitted That Met QC Criteria: November 15, 2017
• First Posted (Actual): November 17, 2017

Study Record Updates

• Last Update Posted (Actual): January 13, 2020
• Last Update Submitted That Met QC Criteria: December 30, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Keywords: lung cancer; lung metastases; lung carcinoma
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Antineoplastic Agents; Photosensitizing Agents; Dermatologic Agents; Dihematoporphyrin Ether; Trioxsalen
• Other Study ID Numbers: CLI-PHO1701

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: This is a phase 2 study with only 10 subjects which is of minor use to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No